CD20, His & Avi, Human
CD20, His & Avi, Human

Immobilized Human CD20 at 1 μg/ml (100 μl/Well), dose response curve for rituximab with the EC50 of 0.8 μg/ml determined by ELISA.

CD20, His & Avi, Human

Human CD20 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.

CD20, His & Avi, Human

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117 ) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
Z03630
¥63,438.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CD20 (Ile141-Ser188)
Accession # P11836		 Poly-His Avi
N-term C-term
Purity > 95% as analyzed by SDS-PAGE
Endotoxin Level ≤ 1 EU/μg of protein by LAL method
Biological Activity Immobilized Human CD20 at 1.0 μg/ml (100 μl/Well), dose response curve for rituximab with the EC50 of 0.8 μg/ml determined by ELISA.
Expression System E. coli
Apparent Molecular Weight ~16.8 kDa, on SDS-PAGE under reducing conditions.
Formulation Supplied as a 0.22 μm filtered solution in 20 mM PB, 10% glycerol, pH 7.0.
Concentration Please refer to the COA for the specific lot.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -70°C or below, the product can be stored for 2-3 weeks at 2-8°C or 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Examples
  • CD20, His & Avi, Human
    • CD20, His & Avi, Human

    Immobilized Human CD20 at 1 μg/ml (100 μl/Well), dose response curve for rituximab with the EC50 of 0.8 μg/ml determined by ELISA.

  • CD20, His & Avi, Human
    • CD20, His & Avi, Human

    Human CD20 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.


Background
Target Background B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117 ) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
Synonyms MS4A1; CD20; MS4A-1; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 11

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.